Data from Mathematical Modeling of Cancer Immunotherapy and Its Synergy with Radiotherapy

• DOI: 10.1158/0008-5472.c.6508790
• Publication Date: 2024-03-12T22:52:56Z
• Authors: Raphael Serre; Sebastien Benzekry; Laetitia Padovani; Christophe Meille; Nicolas André; Joseph Ciccolini; Fabrice Barlesi; Xavier Muracciole; Dominique Barbolosi
• Keywords: Cancer Immunotherapy

<div>Abstract<p>Combining radiotherapy with immune checkpoint blockade may offer considerable therapeutic impact if the immunosuppressive nature of tumor microenvironment (TME) can be relieved. In this study, we used mathematical models, which illustrate potential synergism between inhibitors and radiotherapy. A discrete-time pharmacodynamic model combination PD1–PDL1 axis and/or CTLA4 pathway is described. This framework describes how a growing first elicits then inhibits an antitumor response. response described by primary secondary (or memory) The appears inhibited axis, whereas happens next pathway. effects irradiation are modified version linear-quadratic model. modeling offers explanation for reported biphasic relationship size its immunogenicity, as measured abscopal effect (an off-target response). Furthermore, it explains why discontinuing immunotherapy result in either recurrence or durably sustained Finally, synchronizing produce synergies. ability to forecast endpoints was validated retrospectively checking that could describe data from experimental studies, investigated inhibitors. summary, such further simulation tool facilitate decision making about optimal scheduling perhaps other types anticancer therapies. <i>Cancer Res; 76(17); 4931–40. ©2016 AACR</i>.</p></div>